ArticlePloS one2026
Optimizing topical antibiotic delivery in dogs: Tear film pharmacokinetics of moxifloxacin following pre-treatment with hyaluronic acid.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibiotics in Veterinary Ophthalmology: Resistance, Stewardship, and Emerging Antibiotic-Sparing Strategies.Veterinary ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the impact of pre-treatment with mucoadhesive polymers on tear film concentrations of topically administered moxifloxacin in dogs.
methodsEight healthy dogs were enrolled in a randomized paired-eye crossover study consisting of two sessions (7-day washout). Eyes received topical 0.5% moxifloxacin alone (control) or following pre-treatment with a mucoadhesive polymer applied 30 seconds earlier: either 0.2% hyaluronic acid (HA; Hylogel®) or 0.75% cross-linked hyaluronic acid (XHA; Oculenis®). Tear samples were collected using microcapillary tubes at baseline and predefined intervals up to 480 minutes, and moxifloxacin concentrations were quantified by UV-Vis spectrophotometry (293 nm).
resultsTotal moxifloxacin exposure (AUC0-480) increased following pre-treatment with either HA formulation. The XHA produced a statistically significant 2.0-fold increase in mean AUC0-480 over control (47,929 vs. 24,417 µg·min/mL; P = 0.005). The HA group achieved a 1.8-fold increase in mean AUC0-480 (37,104 vs. 20,693 µg·min/mL), but this did not reach statistical significance (P = 0.154). In the XHA trial, a significant treatment effect (P = 0.012) and interaction (P = 0.002) were observed for concentration, which remained significantly higher than control for 15 minutes (P ≤ 0.018). In the HA trial, a significant treatment effect was noted for concentration (P = 0.020), with levels remaining significantly higher than control for 10 minutes (P ≤ 0.024). No ocular irritation was observed.
conclusionPrior administration of mucoadhesive polymers increases moxifloxacin bioavailability on the canine ocular surface, with this effect being more pronounced for cross-linked HA ("reservoir effect") compared to linear HA formulations. These findings may help optimize topical antibiotic delivery strategies in dogs with bacterial keratitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.